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Abstract 
Purpose: To investigate the potential role of checkpoint kinase2 (CHEK2) in regulating gastric cancer 
stem cells.  
Methods: The abnormal features of cellular arrangements in early and advanced stages of gastric 
cancer were analysed using histology. Immunohistochemistry and Western blotting were used to 
evaluate the expressions of cancer stem cell markers CD44 and CHEK2 at different stages of gastric 
cancer.  
Results: When compared with the control tissue, the size of the cellular nucleus was enlarged as the 
gastric tumour developed to more advanced stages, and the expression of CD44 increased 
exponentially. The expression of CHEK2, a protein that regulates cell cycle and apoptosis was 
aberrantly up-regulated at the early stage of cancer, but as the tumour advanced, its expression 
became down-regulated.  
Conclusion: These results show that the higher expression of CHEK2 at the early stages of gastric 
cancer exerts control over gastric cancer stem cell proliferation. Thus, CHECK2 is a potential target for 
early treatment of gastric cancer.  
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Gastric cancer is a tumour that develops inside 
the lining of the stomach, and it constitutes a 
major health problem worldwide [1,2]. When it is 
not treated at the early  stage, it can spread to 
other organs in the body like liver, abdomen, 
lungs, bones and lymph nodes [3]. Due to the 
nature of its occurrence and metastasis capacity, 
gastric cancer ranks third as the most leading 
cause of cancer  mortality [4]. The aetiology of 
gastric cancer is associated with many 
environmental factors such as dietary patterns, 
Helicobacter pylori infection and host response 
[5,6]. Although the 5-year survival of gastric 
cancer has continued to improve, it is still poor, 
considering that the median survival is less than 
one year for patients diagnosed with 
metastasized gastric cancer [7-9].   
 
Cancer stem cells are small population of cells 
that possess stem cell-like properties which are 
responsible for the resistance to treatment, as 
well as the aggressive nature of cancer [10-12]. 
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To control the incidence of gastric cancer, and to 
provide effective treatment, there is an urgent 
need to identify effective biomarkers with 
therapeutic value that are linked with cancer 
stem cells [13,14]. Checkpoint kinase2 (CHEK2) 
gene monitors checkpoints of the cell cycle that 
regulate cell division. Mutation in CHEK2 gene 
results in the development of cancer types like 
colorectal [15], breast [16], and prostate [17]. 
When subjected to genomic stress, p53 and 
CHEK2 are activated by ataxia telangiectasia 
mutated (ATM) protein, and thereby involved in 
DNA repair, regulate cell cycle and senescence 
[18,19]. It is important to investigate the 
expression of CHEK2 at different stages of 
tumour progression along with markers of cancer 
stem cells, so as to reveal their link with cancer 
stem cell, specifically with cancer progression. 
The present study was carried out to investigate 
the level of expression of CHEK2 and markers of 
gastric cancer stem cell so as to identify their 




Clinical samples from patients 
 
Tissues from early stage and metastasis form of 
gastric cancer were obtained from 126 patients 
(68 males and 58 females) who underwent 
treatment at the Department of Gastrointestinal 
Surgery, Ren Ji Hospital, School of Medicine, 
from June 2012 to October 2015. The median 
age of the patients was 54 years (ages ranged 
from 43 to 68). The patients were examined, and 
gastric cancer tissue samples were removed for 
further analysis. The patients are subjected to 
open surgery, or to laparoscopy-assisted 
gastrectomy in line with international guidelines 
recommended by Japanese Gastric Cancer 
Association [20].  On the whole, 32 samples 
were with normal gastric mucosa, 66 samples 
had early stage of cancer, while 28 samples had 
advanced stage of gastric cancer.  The study 
was approved by the Institutional Review Board 




The samples were washed with distilled water 
and fixed with 10 % formalin solution. After 48 h 
of fixation, the gastric tissue samples were once 
again washed with water and subjected to 
dehydration process. The samples were 
transferred to increasing concentrations of 
ethanol (60, 70, 80, 90 and 100 %) for complete 
removal of water, and the dehydrated tissue 
samples were cleared in xylene for 45 min. The 
tissues were then impregnated with liquid wax, 
and traces of xylene were completely removed 
by transferring to fresh liquid wax. The tissues 
were finally embedded in paraffin after overnight 
incubation. They were subsequently sectioned 
with microtome to 6 µm slices which were 




The dissected sections were de-waxed, and their 
endogenous peroxide activity was specifically 
blocked by incubating in 10 % H2O2.  After 
blocking the non-specific sites with 5 % BSA 
solution, the tissues were incubated with primary 
antibody anti-CD44 (Abcam, ab51037) or anti-
CHEK2 (Abcam, ab109413) overnight at 4 ºC. 
After washing the sections with 1X PBS, the 
tissues are overlaid with appropriate secondary 
antibody for 2 h at room temperature. The 
sections were washed twice with 1X PBS, and 




Pre-chilled tissues were homogenized in 2X 
protein sample buffers and heated in boiling 
water bath for 5 min to separate the protein 
samples. Protein estimation was done using 
Lowry method [21], and each lane of the gel was 
loaded with 80 µg of protein samples to resolve 
them in 12 % SDS PAGE gel. When the dye 
reached the bottom of the protein, the gel was 
transferred to PVDF membrane. The membrane 
was then incubated in 5 % skimmed milk powder 
in TBST for 2 h at room temperature, and 
thereafter incubated with primary antibody anti-
CD44 (Abcam, ab51037) or anti-CHEK2 (Abcam, 
ab109413) overnight at 4 ºC. Non-specific 
binding of antibody was washed out thrice with 
TBST solution, and the membrane was further 
incubated with HRP-conjugated suitable 
secondary antibody for 1 h at room temperature. 
After final washing with TBST solution, the 




The assays carried out were carried out in 
triplicate and the results presented as mean ± 
SD. The data were statistically analysed using 
student t-test and one-way analysis of variance 
(ANOVA). Values of p less than 0.05 were 




Changes in gastric tissue morphology  
 
The histology of gastric tissue from the control 
group showed distinct cells with nuclei evenly 
distributed throughout the tissue layer, with 
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mucosa layer nuclei being small in size (Figure 1 
A). On the other hand, the histological section of 
early stage gastric cancer tissue showed 
enlarged nuclei with some of the cells clumped 
together, and the cells had irregular structures 
(Figure 1 B). Initiation of signet ring cell was also 
observed, which is a characteristic feature of 
gastric cancer (Figure 1 B). Gastric tissue from 
advanced stage gastric cancer showed larger 
nuclei than in early stage gastric cancer, with 
pronounced distortion of the regular tissue 
pattern (Figure 1 C). Irregular polygonal tumour 
cells with aggressive cellular proliferation were 




Figure 1: Morphology of early and advanced stage 
gastric cancer tissues, (A): Control gastric tissue 
subjected to histological analysis showing cells with 
minimal and normal size nuclei, (B): Early stage 
gastric cancer showing enlarged nuclei and initiation of 
signet ring cells, (C): Advanced stage gastric cancer 
with irregular polygonal tumour cells and highly 
proliferative cells 
 
Correlation between CD44 and CHEK2 
expressions 
 
CD44 is an adhesion molecule that exists on the 
cell surface of gastric cancer stem cells, and it 
plays a role in tissue invasion [22]. Using 
immunohistochemistry, the expression profiles of 
CD44 and CHEK2 were analysed to understand 
their link with each other. In the control tissue, 
the expression of CD44 was highly restricted with 
low or minimum signals (Figure 2 A). However, 
CD44 expression was up-regulated in early 
gastric cancer (Figure 2 B), and showed multi-
fold increase as the tumour developed to an 
advanced stage (Figure 2 C). Similarly, the 
expression of CHEK2 showed minimal signals in 
control tissue (Figure 2D), but an increased 
pattern of expression was evident in early stage 
gastric cancer (Figure 2 E). As the tumour 
developed to the advanced stage, statistically 
significant down-regulation of CHEK2 signals 
was observed (Figure 2 F). 
 
Expression of CD44 and CHEK2  
 
Immuno-histochemical data were further 
analysed using western blotting. The expression 
profiles of CD44 and CHEK2 were minimal in the 
control tissue (Figure 3, Lane 1), but in the early 
stage gastric cancer, their expressions became 
up-regulated (Figure 3, Lane 2). The expression 
of CD44 showed an up-regulated pattern as the 
tumour progressed to the advanced stage, but 
CHEK2 expression was down-regulated (Figure 




Figure 2: Immuno-histochemical analysis of the 
correlation between CD44 and CHEK2 expression. 
(A): Weak expression of CD44 in control gastric tissue, 
(B): Moderate expression of CD44 in early stage 
gastric cancer, (C): Advanced stage gastric cancer 
with significant over-expression, (D): Control gastric 
tissue showing faint expression of CHEK2, (E): 
Upregulated expression of CHEK2 in early stage 
gastric cancer, (F): Prominent down-regulation of 




Figure 3: Results of Western Blotting with anti-CD44 
and anti-CHEK2 antibodies. Row 1: expressions of 
gastric cancer stem cell marker CD44 in control (Lane 
1), in initial stage gastric cancer (Lane 2), and in 
advanced stage gastric cancer (Lane 3).  Row 2: 
expressions of CHEK2 in control (Lane 1), in initial 
stage gastric cancer (Lane 2) and in advanced stage 
gastric cancer (Lane 3).  Row 3: Loading control β-




Research in the area of gastric cancer stem cells 
has generated much interest in the last two 
decades because these stem cells are linked to 
the aetiology of gastric cancer [23]. 
Understanding the behaviour of gastric cancer 
stem cells in different grades of cancer aids in 
devising ways of inhibiting them, which is of 
therapeutic value. Various proteins regulate 
gastric cancer stem cell properties. These 
include Bmi-1 [24] and Sox2 [22]. Detailed 
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understanding of these regulatory proteins may 
result in significant contributions to acceptable 
prognosis of gastric cancer. It has been reported 
that the expression of CHEK2 is down-regulated 
with advancement in stages of prostate cancer 
[25]. 
 
In the present investigation, the expression 
profile of CHEK2 in the early and advanced 
stages of gastric cancer, and the expression of 
gastric cancer stem cell marker was analysed. 
Results from histology revealed that as the 
tumour progressed, the gastric tissue cells 
become complex in nature and invaded 
neighbouring tissues.  CD44 is a cell surface 
gastric stem cell marker that plays a major role in 
adhesion and tissue invasion [22]. Recent 
studies related to CD44 found that the 
suppression of gastric cancer works by targeting 
CD44 through miR-145 [26]. 
 
In the current study, data from 
immunohistochemistry and western blotting 
revealed that at the initial stage of gastric tumour, 
the expression of CD44 was raised, but the 
increase in expression was comparatively more 
at the advanced stage of cancer. From the 
results, it can be inferred that the chemo-
resistance behaviour of gastric cancer occurs at 
the advanced stage of cancer due to increasing 
population of gastric cancer stem cells. The 
expression of CHEK2 followed a similar pattern 
as that of CD44 in normal and early stage of 
gastric cancer tissue, but the expression pattern 
of CHEK2 was down-regulated as the tumour 
developed to the advanced stage. By correlating 
the results with results from cancer studies, it can 
be inferred that in response to tumour 
development, the cell expresses more CHEK2 
protein to control abnormal cell proliferation in 
early stage of gastric cancer, but in the advance 
stage of gastric cancer the expression of CHEK2 
is down-regulated, resulting in loss of significant 




The results of the current study suggest that the 
higher expression of CHEK2 at the early stages 
of gastric cancer exerts control over gastric stem 
cells. Thus, treatment at this stage would 
produce better outcomes than treatment at the 
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